About a year after getting the FDA thumbs-up for its blockbuster cystic fibrosis drug Trikafta, Vertex is picking up where it left off. The Boston-based biotech read out positive results from a Phase III study involving children ages 6 to 11, and announced plans to file for a supplemental NDA later this year. Previously, the … Continue reading A year out from FDA approval, Vertex looks to expand top-selling CF drug to pediatrics